Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Best of ASCO 2021

Best of ASCO 2021 editorial memo (2021) 14:313–314 https://doi.org/10.1007/s12254-021-00768-4 Ewald Wöll Accepted: 29 September 2021 © Springer-Verlag GmbH Austria, part of Springer Nature 2021 In the current issue of the Magazine of European Med- Drs. Absenger and Pircher highlight their non-small ical Oncology (MEMO), we provide a series of articles cell lung cancer favorites. First data on adjuvant ate- summarizing the most relevant presentations deliv- zolizumab show promising results. In addition two ered at ASCO 2021 on central nervous system tumors, trials in resected EGFR-mutated patients elucidating upper gastrointestinal (GI)cancers, triple-negative the effect of neo/adjuvant treatment with gefitinib or breast cancer (TNBC), nasopharyngeal carcinoma, erlotinib are reported [5]. early stage non-small cell lung cancer, advanced ovar- Drs. Schöche and Strasser-Weippl present the ther- ian cancer, bladder cancer, and metastastic colorectal apeutic medical landscape in advanced ovarian can- cancer. cer and several interesting studies that might have Drs. Berghoff and Mair discuss recent advances in aclinical impact inthe future [6]. central nervous system tumors. The data presented Drs. Mayrhofer, K. and Niedersüß-Beke review show interesting aspects of molecular platform diag- the papers on bladder cancer. Three phase II trials nostics and promising results on targeted therapies address the incorporation of immunotherapy in in- [1]. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Loading next page...
 
/lp/springer-journals/best-of-asco-2021-V0YrNueP94

References (9)

Publisher
Springer Journals
Copyright
2021 Springer-Verlag GmbH Austria, part of Springer Nature
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-021-00768-4
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2021) 14:313–314 https://doi.org/10.1007/s12254-021-00768-4 Ewald Wöll Accepted: 29 September 2021 © Springer-Verlag GmbH Austria, part of Springer Nature 2021 In the current issue of the Magazine of European Med- Drs. Absenger and Pircher highlight their non-small ical Oncology (MEMO), we provide a series of articles cell lung cancer favorites. First data on adjuvant ate- summarizing the most relevant presentations deliv- zolizumab show promising results. In addition two ered at ASCO 2021 on central nervous system tumors, trials in resected EGFR-mutated patients elucidating upper gastrointestinal (GI)cancers, triple-negative the effect of neo/adjuvant treatment with gefitinib or breast cancer (TNBC), nasopharyngeal carcinoma, erlotinib are reported [5]. early stage non-small cell lung cancer, advanced ovar- Drs. Schöche and Strasser-Weippl present the ther- ian cancer, bladder cancer, and metastastic colorectal apeutic medical landscape in advanced ovarian can- cancer. cer and several interesting studies that might have Drs. Berghoff and Mair discuss recent advances in aclinical impact inthe future [6]. central nervous system tumors. The data presented Drs. Mayrhofer, K. and Niedersüß-Beke review show interesting aspects of molecular platform diag- the papers on bladder cancer. Three phase II trials nostics and promising results on targeted therapies address the incorporation of immunotherapy in in- [1].

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Dec 1, 2021

Keywords: oncology; medicine/public health, general

There are no references for this article.